We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) to Report Q1 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) is set to release first-quarter 2021 results on Apr 22, before market open.
The company delivered better-than-expected results in each of the last four quarters, the earnings surprise being 19.86%, on average. In the last reported quarter, the company’s earnings of $2.08 per share surpassed the Zacks Consensus Estimate of $1.84 by 13.04%.
In the past three months, Danaher’s shares have gained 3.8% compared with the industry’s growth of 12.3%.
Factors at Play
Danaher is expected to have benefited from growth in demand for its products, along with its focus on product innovation and operational execution, in the first quarter of 2021. For the first quarter, the company increased its core sales growth projection (including Cytiva) to 29% from the growth of mid-to high-teens range guided previously.
Notably, the company expects total revenues for the first quarter to increase 57% on a year-over-year basis. It is likely to have benefited from strong momentum across its businesses, with particular strength in the Diagnostics and Life Sciences segments.
Coming to operating segments, healthy demand for bioprocessing products is likely to have augmented the top-line performance of its Life Sciences segment. The Zacks Consensus Estimate for the Life Sciences segment’s revenues is pegged at $2,943 million, suggesting a 78.4% year-over-year increase but 12.4% sequential decline.
For the Diagnostics segment, solid demand for molecular testing products is anticipated to have supported its performance. The Zacks Consensus Estimate for the Diagnostics segment’s revenues for the first quarter is pegged at $2,000 million, suggesting growth of 22.9% from the year-ago reported figure but a decrease of 10.2% on a sequential basis.
For the Environmental & Applied Solutions segment, the company anticipates healthy consumables business and a solid demand for equipment to have boosted the segment’s performance. The consensus estimate for the segment’s revenues is pegged at $1,109 million, indicating growth of 4% from the year-ago reported number but a sequential fall of 5.4%.
The Zack Consensus Estimate for first-quarter total revenues of $6,076 million suggests a 39.9% increase from the year-ago reported figure but 10.1% decline from the previous quarter’s reported number.
However, the coronavirus outbreak-related issues along with an unwarranted rise in costs and expenses and high debts, if any, might have affected Danaher‘s performance in the quarter. In addition, given its diverse geographic presence, its operations are subject to issues like unfavorable movement in foreign currencies and interest rate fluctuations in some foreign countries. This might have hurt its business in the to-be-reported quarter as well.
Earnings Whispers
Our proven model predicts an earnings beat for Danaher this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
This is the case here as given below:
Earnings ESP: The company has an Earnings ESP of +4.11% as the Most Accurate Estimate is pegged at $1.74, higher than the Zacks Consensus Estimate of $1.67.
Here are some other companies that you may want to consider as our model shows that these too have the right combination of elements to post an earnings beat this quarter:
Honeywell International Inc. (HON - Free Report) has an Earnings ESP of +2.31% and a Zacks Rank #3.
ITT Inc. (ITT - Free Report) has an Earnings ESP of +2.39% and Zacks Rank #3.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Image: Bigstock
Danaher (DHR) to Report Q1 Earnings: Is a Beat in the Cards?
Danaher Corporation (DHR - Free Report) is set to release first-quarter 2021 results on Apr 22, before market open.
The company delivered better-than-expected results in each of the last four quarters, the earnings surprise being 19.86%, on average. In the last reported quarter, the company’s earnings of $2.08 per share surpassed the Zacks Consensus Estimate of $1.84 by 13.04%.
In the past three months, Danaher’s shares have gained 3.8% compared with the industry’s growth of 12.3%.
Factors at Play
Danaher is expected to have benefited from growth in demand for its products, along with its focus on product innovation and operational execution, in the first quarter of 2021. For the first quarter, the company increased its core sales growth projection (including Cytiva) to 29% from the growth of mid-to high-teens range guided previously.
Notably, the company expects total revenues for the first quarter to increase 57% on a year-over-year basis. It is likely to have benefited from strong momentum across its businesses, with particular strength in the Diagnostics and Life Sciences segments.
Coming to operating segments, healthy demand for bioprocessing products is likely to have augmented the top-line performance of its Life Sciences segment. The Zacks Consensus Estimate for the Life Sciences segment’s revenues is pegged at $2,943 million, suggesting a 78.4% year-over-year increase but 12.4% sequential decline.
For the Diagnostics segment, solid demand for molecular testing products is anticipated to have supported its performance. The Zacks Consensus Estimate for the Diagnostics segment’s revenues for the first quarter is pegged at $2,000 million, suggesting growth of 22.9% from the year-ago reported figure but a decrease of 10.2% on a sequential basis.
For the Environmental & Applied Solutions segment, the company anticipates healthy consumables business and a solid demand for equipment to have boosted the segment’s performance. The consensus estimate for the segment’s revenues is pegged at $1,109 million, indicating growth of 4% from the year-ago reported number but a sequential fall of 5.4%.
The Zack Consensus Estimate for first-quarter total revenues of $6,076 million suggests a 39.9% increase from the year-ago reported figure but 10.1% decline from the previous quarter’s reported number.
However, the coronavirus outbreak-related issues along with an unwarranted rise in costs and expenses and high debts, if any, might have affected Danaher‘s performance in the quarter. In addition, given its diverse geographic presence, its operations are subject to issues like unfavorable movement in foreign currencies and interest rate fluctuations in some foreign countries. This might have hurt its business in the to-be-reported quarter as well.
Earnings Whispers
Our proven model predicts an earnings beat for Danaher this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
This is the case here as given below:
Earnings ESP: The company has an Earnings ESP of +4.11% as the Most Accurate Estimate is pegged at $1.74, higher than the Zacks Consensus Estimate of $1.67.
Danaher Corporation Price and EPS Surprise
Danaher Corporation price-eps-surprise | Danaher Corporation Quote
Zacks Rank: Danaher carries a Zacks Rank #3.
Other Key Picks
Here are some other companies that you may want to consider as our model shows that these too have the right combination of elements to post an earnings beat this quarter:
General Electric Company (GE - Free Report) has an Earnings ESP of +33.33% and it currently carries a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Honeywell International Inc. (HON - Free Report) has an Earnings ESP of +2.31% and a Zacks Rank #3.
ITT Inc. (ITT - Free Report) has an Earnings ESP of +2.39% and Zacks Rank #3.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>